Med2Date — Clinical Guidelines
Home Endocrinology Hyponatraemia

Hyponatraemia

Last updated 24 Mar 2026 · Metabolic Bone Disease

Summary Key Points

📋
Clinical Definition: Hyponatraemia is defined as serum sodium concentration <135 mmol/L, representing the most common electrolyte abnormality encountered in Australian healthcare settings.
Mild Hyponatraemia
130-134 mmol/L
Moderate Hyponatraemia
125-129 mmol/L
Severe Hyponatraemia
<125 mmol/L
1
Assessment Priority
Evaluate symptom severity and onset (acute <48 hours vs chronic >48 hours) as this determines correction rate and risk of cerebral oedema vs osmotic demyelination syndrome
2
Volume Status Classification
Determine hypovolaemic, euvolaemic, or hypervolaemic state through clinical examination and targeted investigations to guide specific management
3
Correction Rate Limits
Chronic hyponatraemia: maximum 8-10 mmol/L/day correction; acute symptomatic: may correct more rapidly initially but monitor closely for overcorrection
🚨
Emergency Management: Severe symptomatic hyponatraemia with seizures, coma, or altered consciousness requires immediate treatment with 3% saline 100-150mL IV over 20 minutes, with urgent endocrine consultation.
Common Causes in Australia
  • SIADH: Malignancy, CNS disorders, pulmonary disease, medications (SSRIs, carbamazepine, PPIs)
  • Volume depletion: Diuretics, GI losses, adrenal insufficiency
  • Heart failure: Advanced stages with fluid retention
  • Endocrine: Hypothyroidism, adrenal insufficiency
  • Iatrogenic: Hypotonic fluid administration, post-operative
High-Risk Populations
  • Elderly patients: Increased susceptibility to medication-induced hyponatraemia
  • Hospitalised patients: Post-operative, receiving hypotonic fluids
  • Psychiatric patients: Psychogenic polydipsia, SSRI therapy
  • Malignancy patients: SIADH, adrenal metastases
  • Chronic disease: Heart failure, cirrhosis, CKD
⚠️
Osmotic Demyelination Risk: Overcorrection of chronic hyponatraemia (>12 mmol/L/day) can cause central pontine myelinolysis. Higher risk in alcoholism, malnutrition, liver disease, and elderly patients.
Mild
130-134 mmol/L
Usually asymptomatic, may have mild fatigue
Outpatient management
Moderate
125-129 mmol/L
Nausea, headache, confusion, weakness
Hospital monitoring
Severe
<125 mmol/L
Seizures, coma, cerebral oedema
ICU/HDU management
✅
Australian Context: PBS covers essential medications including fludrocortisone for adrenal insufficiency and desmopressin for diabetes insipidus. Specialist endocrine consultation recommended for complex cases, particularly through public hospital networks and Medicare-funded specialist services.
Key Monitoring Parameters
  • Serum sodium every 4-6 hours during acute correction
  • Neurological status and symptom monitoring
  • Urine sodium and osmolality for diagnostic workup
  • Volume status assessment (weight, fluid balance)
  • Thyroid and adrenal function if indicated

Introduction & Australian Epidemiology

Hyponatraemia, defined as serum sodium concentration less than 135 mmol/L, is the most common electrolyte abnormality encountered in clinical practice worldwide and represents a significant healthcare burden in Australia. This condition ranges from mild, asymptomatic biochemical abnormalities to life-threatening neurological emergencies requiring immediate intervention.

ℹ️
Definition: Hyponatraemia is classified as mild (130-134 mmol/L), moderate (125-129 mmol/L), or severe (<125 mmol/L), with severity of symptoms often correlating with both the degree and rapidity of sodium decline.

Australian Epidemiology

Australian hospital data indicates that hyponatraemia affects approximately 15-30% of hospitalised patients, with higher prevalence in:

  • Elderly populations: Up to 25% of residents in aged care facilities
  • Acute care settings: Present in 30-42% of emergency department presentations
  • ICU patients: Occurs in 25-30% of critically ill patients
  • Psychiatric inpatients: Prevalence of 20-25%, often medication-induced
Hospital Burden
  • Associated with 2-7 fold increased mortality risk
  • Extends average hospital length of stay by 2-4 days
  • Increases healthcare costs by approximately $3,000-5,000 per admission
  • Accounts for ~15,000 additional hospital bed-days annually in Australia
Australian Risk Factors
  • Advanced age (>65 years)
  • Polypharmacy (especially diuretics, antidepressants)
  • Chronic diseases (heart failure, cirrhosis, CKD)
  • Post-operative states
  • Malignancy and paraneoplastic syndromes

Regional Considerations

Specific challenges in the Australian healthcare context include:

Urban Centres
Tertiary Care Access
Comprehensive endocrinology and nephrology services available. Access to advanced diagnostic modalities and specialised hyponatraemia management units in major metropolitan hospitals.
Major cities: Sydney, Melbourne, Brisbane, Perth, Adelaide
Regional Areas
Limited Specialist Access
Reliance on telehealth consultations and general practitioner management. Delayed specialist review may impact complex cases requiring detailed volume status assessment.
Regional hospitals and rural centres
Remote/Very Remote
Resource Constraints
Limited access to frequent laboratory monitoring and specialist input. Potential for delayed recognition and treatment, particularly in Aboriginal and Torres Strait Islander communities.
Remote Area Health Services, RFDS coverage areas
⚠️
Clinical Impact: Mild hyponatraemia (130-134 mmol/L) increases fall risk by 67% in elderly patients and is associated with attention deficits and gait instability even when asymptomatic. Severe hyponatraemia (<125 mmol/L) carries significant neurological morbidity and mortality risk if not managed appropriately.

Healthcare System Integration

This guideline aligns with Australian healthcare standards and frameworks:

  • ACSQHC NSQHS Standards: Supports Clinical Governance (Standard 1) and Comprehensive Care (Standard 5)
  • PBS Integration: Prioritises PBS-listed therapies for sustainable treatment pathways
  • My Health Record: Facilitates care coordination across multiple providers
  • Quality Use of Medicines: Emphasises medication reconciliation and deprescribing strategies

The management approach outlined in this guideline incorporates contemporary international evidence while accounting for Australian-specific factors including geographic isolation, Indigenous health considerations, PBS restrictions, and integration with existing care pathways in both metropolitan and rural settings.

Pathophysiology

💧
Key Concept: Hyponatraemia represents a disturbance in water homeostasis rather than sodium deficiency, with serum osmolality determining clinical manifestations.

Normal Sodium and Water Homeostasis

Serum sodium concentration is tightly regulated between 135-145 mmol/L through coordinated mechanisms involving:

  • Antidiuretic hormone (ADH/vasopressin) - Released from posterior pituitary in response to increased serum osmolality (>295 mOsm/kg) or decreased effective circulating volume
  • Renal concentration mechanisms - Ability to concentrate urine up to 1200 mOsm/kg and dilute to 50 mOsm/kg
  • Thirst mechanism - Stimulated by hypothalamic osmoreceptors at ~295 mOsm/kg
  • Renal sodium handling - Aldosterone-mediated sodium retention and natriuretic peptide-mediated sodium loss

Pathophysiological Mechanisms

1. Hypotonic Hyponatraemia (Most Common - 95% of cases)

Results from excess water retention relative to sodium, leading to cellular oedema and neurological symptoms.

A
Hypovolaemic Hyponatraemia
Loss of sodium > loss of water. ADH appropriately released to preserve intravascular volume despite hypo-osmolality. Common causes: diuretics, diarrhoea, vomiting, cerebral salt wasting.
B
Euvolaemic Hyponatraemia
Inappropriate ADH release or action despite normal/low serum osmolality. Water retention without significant sodium loss. SIADH, hypothyroidism, adrenal insufficiency.
C
Hypervolaemic Hyponatraemia
Impaired water excretion due to reduced effective circulating volume. Total body sodium increased but diluted. Heart failure, cirrhosis, nephrotic syndrome, CKD.

2. Isotonic Hyponatraemia (Pseudohyponatraemia)

Normal serum osmolality (280-295 mOsm/kg) with low measured sodium due to:

  • Severe hyperproteinaemia - Protein >100 g/L (myeloma, hypergammaglobulinaemia)
  • Severe hyperlipidaemia - Triglycerides >35 mmol/L (>3000 mg/dL)
  • Laboratory artifact - Ion-selective electrode interference

3. Hypertonic Hyponatraemia

Elevated serum osmolality (>295 mOsm/kg) with low sodium due to osmotic water shift:

  • Hyperglycaemia - Each 5.5 mmol/L glucose elevation decreases sodium by ~1.6 mmol/L
  • Mannitol administration - Osmotic diuresis with water shift
  • Hypernatraemia correction - Rapid glucose correction causing water redistribution

Syndrome of Inappropriate ADH Secretion (SIADH)

Most common cause of euvolaemic hyponatraemia, characterised by:

SIADH Criteria (Schwartz-Bartter)
  • Serum sodium <135 mmol/L
  • Serum osmolality <275 mOsm/kg
  • Urine osmolality >100 mOsm/kg
  • Urine sodium >30 mmol/L (on normal salt diet)
  • Clinical euvolaemia
  • Normal thyroid/adrenal function
  • No recent diuretic use
Common SIADH Causes
  • Malignancy: Lung, pancreas, duodenum, uroepithelial
  • CNS disorders: Meningitis, encephalitis, stroke, trauma
  • Pulmonary: Pneumonia, TB, positive pressure ventilation
  • Medications: SSRIs, carbamazepine, cyclophosphamide
  • Other: Post-operative state, pain, nausea
⚠️
Australian Context: In elderly Australians, medication-induced SIADH (particularly SSRIs and thiazides) accounts for >40% of cases. Always review medications including over-the-counter NSAIDs.

Cellular Consequences and Adaptation

Acute Hyponatraemia (<48 hours)

Rapid cellular swelling due to osmotic water influx, particularly affecting brain cells:

  • Cerebral oedema and increased intracranial pressure
  • Altered consciousness, seizures, coma
  • Risk of herniation if severe (<120 mmol/L)
  • Limited cellular adaptation time

Chronic Hyponatraemia (>48 hours)

Cellular adaptation through organic osmolyte loss reduces brain swelling:

  • Phase 1 (minutes-hours): Loss of intracellular electrolytes (K+, Cl-)
  • Phase 2 (hours-days): Loss of organic osmolytes (taurine, glutamate, myo-inositol)
  • Reduced cerebral oedema but persistent cognitive impairment
  • Risk of osmotic demyelination if corrected too rapidly

Osmotic Demyelination Syndrome (ODS)

Devastating complication of overly rapid sodium correction in chronic hyponatraemia:

Mechanism
Cellular Dehydration
Rapid sodium rise causes osmotic water efflux from adapted brain cells, leading to oligodendrocyte injury and demyelination
Location
Central Pontine
Central pons most commonly affected (central pontine myelinolysis), but can occur in extrapontine areas (basal ganglia, thalamus)
Risk Factors
High-Risk Patients
Alcoholism, malnutrition, liver disease, hypokalaemia, elderly females on thiazides

Age-Related Pathophysiological Considerations

👴 Elderly Patients
Reduced GFR Impaired diluting capacity, increased thiazide sensitivity
Medication Effects Polypharmacy increases SIADH risk (SSRIs, PPIs, ACE inhibitors)
Cognitive Impact Falls risk increased even with mild hyponatraemia (130-135 mmol/L)
👶 Paediatric Patients
Brain Water Content Higher baseline brain water content increases oedema risk
Immature Kidneys Reduced concentrating ability in neonates and infants
Rapid Changes Faster development of symptoms due to smaller blood volume
🚨
Critical Point: The rate of sodium decline, not just the absolute value, determines symptom severity. Acute drops of >10-12 mmol/L in 24 hours can cause seizures even at sodium levels >125 mmol/L.

Classification

ℹ️
Clinical Classification: Hyponatraemia is classified by serum osmolality, volume status, and severity to guide appropriate management strategies.

Severity Classification

MILD
130-134 mmol/L
Usually asymptomatic or mild symptoms
Outpatient management
MODERATE
125-129 mmol/L
Moderate symptoms: nausea, confusion, headache
Hospital assessment recommended
SEVERE
<125 mmol/L
Severe symptoms: altered consciousness, seizures
Emergency management required

Osmolality-Based Classification

Type Serum Osmolality Mechanism Common Causes
Hypotonic
(True hyponatraemia)		 <280 mOsm/kg Excess water relative to sodium SIADH, heart failure, cirrhosis, hypothyroidism
Isotonic
(Pseudohyponatraemia)		 280-295 mOsm/kg Laboratory artefact Severe hyperlipidaemia, hyperproteinaemia
Hypertonic
(Translocational)		 >295 mOsm/kg Osmotic shift of water Hyperglycaemia, mannitol, contrast agents

Volume Status Classification

For hypotonic hyponatraemia, classification by volume status guides treatment approach:

1
Hypovolaemic Hyponatraemia
Clinical features: Dry mucous membranes, decreased skin turgor, orthostatic hypotension
Urine sodium: <30 mmol/L (renal losses) or >30 mmol/L (extra-renal losses)
Treatment principle: Volume replacement with normal saline
2
Euvolaemic Hyponatraemia
Clinical features: No oedema, normal skin turgor, normal blood pressure
Urine sodium: Usually >30 mmol/L
Most common cause: SIADH
Treatment principle: Water restriction, treat underlying cause
3
Hypervolaemic Hyponatraemia
Clinical features: Oedema, elevated JVP, third heart sound
Urine sodium: <30 mmol/L
Common causes: Heart failure, cirrhosis, nephrotic syndrome
Treatment principle: Treat heart failure, diuretics, water restriction

Temporal Classification

🕐 Acute Hyponatraemia
  • Duration: <48 hours
  • Higher risk of cerebral oedema
  • Can correct more rapidly (1-2 mmol/L/hour initially)
  • Often symptomatic at higher sodium levels
📅 Chronic Hyponatraemia
  • Duration: >48 hours (or unknown)
  • Brain adaptation has occurred
  • Risk of osmotic demyelination with rapid correction
  • Correction rate: <8-10 mmol/L/24 hours
🚨
High-Risk Groups for Osmotic Demyelination: Alcoholism, malnutrition, advanced liver disease, hypokalaemia, elderly women on thiazide diuretics. These patients require even slower correction rates (<6 mmol/L/24 hours).

Diagnostic Algorithm Summary

Step 1
Confirm hyponatraemia with repeat serum sodium and assess symptoms
Step 2
Measure serum osmolality to exclude pseudohyponatraemia
Step 3
Assess volume status clinically (hypo/eu/hypervolaemic)
Step 4
Measure urine sodium and osmolality to refine diagnosis
Step 5
Determine chronicity (<48 hours vs >48 hours)
Step 6
Identify underlying cause and commence appropriate treatment

Clinical Presentation & Diagnostic Criteria

⚠️
Clinical Significance: Symptoms correlate more with rate of sodium decline than absolute serum sodium level. Acute hyponatraemia (<48 hours) carries higher risk of cerebral oedema and neurological complications.

Severity Classification

MILD
130-134 mmol/L
Often asymptomatic or minimal symptoms
Outpatient management
MODERATE
125-129 mmol/L
Mild to moderate neurological symptoms
Hospital assessment recommended
SEVERE
<125 mmol/L
High risk of serious complications
Emergency department / inpatient

Clinical Manifestations by System

🧠 Neurological Symptoms

Early/Mild:

  • Headache
  • Nausea and vomiting
  • Fatigue and lethargy
  • Confusion
  • Muscle cramps

Progressive/Severe:

  • Altered mental state
  • Seizures
  • Coma
  • Focal neurological deficits
  • Respiratory depression
⚖️ Physical Signs

General:

  • Altered sensorium
  • Depressed reflexes
  • Hypothermia
  • Cheyne-Stokes breathing

Volume Status Assessment:

  • Hypovolaemic: Dry mucous membranes, reduced skin turgor, hypotension, tachycardia
  • Euvolaemic: Normal volume status
  • Hypervolaemic: Oedema, elevated JVP, pulmonary crackles

Diagnostic Criteria & Assessment

ℹ️
Definition: Serum sodium <135 mmol/L. Pseudohyponatraemia must be excluded (hyperglycaemia, hyperlipidaemia, hyperproteinaemia).
1
Confirm True Hyponatraemia
Exclude pseudohyponatraemia. Calculate corrected sodium if glucose >10 mmol/L: Corrected Na⁺ = measured Na⁺ + 0.3 × (glucose - 5.5)
2
Assess Volume Status
Clinical examination for signs of hypovolaemia, euvolaemia, or hypervolaemia. Consider CVP/echocardiography if unclear.
3
Determine Chronicity
Acute (<48h) vs chronic (>48h). History, previous laboratory results, symptom onset.
4
Symptom Assessment
Neurological symptoms, cognitive function, falls risk, seizure activity.

High-Risk Clinical Scenarios

🚨
Immediate Assessment Required: Serum sodium <120 mmol/L, seizures, coma, acute onset (<48h), elderly patients, concurrent illness, or rapid correction risk.
Clinical Scenario Risk Factors Management Priority
Severe symptomatic hyponatraemia Na⁺ <125 mmol/L, seizures, coma, respiratory compromise Emergency treatment, ICU consideration
Acute hyponatraemia Onset <48h, post-operative, marathon runners Rapid but controlled correction
Elderly with hyponatraemia Age >65, polypharmacy, cognitive impairment Falls assessment, medication review
Post-surgical hyponatraemia Hypotonic fluid administration, pain, nausea Fluid restriction, ADH suppression

Complications of Untreated Hyponatraemia

  • Cerebral oedema: Increased intracranial pressure, herniation syndromes
  • Seizures: Particularly with acute or severe hyponatraemia
  • Cognitive impairment: Attention deficits, memory problems
  • Falls and fractures: Especially in elderly patients
  • Rhabdomyolysis: Severe muscle breakdown
  • Respiratory failure: Central drive depression
✅
Key Clinical Pearls: Symptoms are related to rate of decline rather than absolute sodium level. Chronic hyponatraemia may be well-tolerated. Always assess volume status and chronicity before treatment planning.

Investigations

Initial Laboratory Assessment

All investigations listed are readily available in Australian public and private pathology services unless specified otherwise.

  • Essential
    Serum Sodium (Repeated)
    Confirm hyponatraemia and assess severity. Paired plasma and urine samples collected simultaneously for accurate interpretation. Medicare item: 66500.
  • Essential
    Serum Osmolality
    Calculated osmolality may be inaccurate. Measured osmolality distinguishes true from pseudohyponatraemia. Medicare item: 66506.
  • Essential
    Urine Osmolality
    Essential for determining if kidneys are appropriately concentrating urine. Spot urine adequate if >300 mOsm/kg. Medicare item: 66506.
  • Essential
    Urine Sodium
    Spot urine sodium >30 mmol/L suggests SIADH or salt-wasting. Best interpreted alongside clinical assessment of volume status. Medicare item: 66500.
  • Essential
    Full Blood Count
    Assess for haemoconcentration/dilution. May reveal underlying malignancy or infection. Medicare item: 65070.
  • Essential
    Comprehensive Metabolic Panel
    Include potassium, chloride, bicarbonate, BUN, creatinine, glucose. Assess for other electrolyte disturbances and renal function. Medicare item: 66500-66528.

Hormone Assessment

  • Available
    Thyroid Function Tests
    TSH, free T4. Severe hypothyroidism can cause hyponatraemia through impaired water excretion. Medicare item: 66719, 66734.
  • Available
    Morning Cortisol
    Random cortisol >550 nmol/L excludes adrenal insufficiency. If <275 nmol/L, perform ACTH stimulation test. Medicare item: 66601.
  • Referral
    ACTH Stimulation Test
    Gold standard for diagnosing adrenal insufficiency. Usually performed in endocrinology units. Synacthen 250 μg IM/IV. Medicare item: 66602.
  • Specialist
    Copeptin
    Surrogate marker for AVP/ADH. Limited availability in Australia - mainly research centres. May help distinguish SIADH from other causes.

Imaging Studies

  • Available
    Chest X-Ray
    Screen for malignancy, pneumonia, or other pulmonary pathology causing SIADH. May reveal small cell lung cancer. Medicare item: 58503.
  • Available
    CT Chest/Abdomen/Pelvis
    If malignancy suspected as cause of SIADH. Most common sources: lung, pancreas, duodenum. Medicare item: 56001-56507.
  • Available
    MRI Brain
    If central nervous system pathology suspected. Assess hypothalamic-pituitary axis if symptoms suggest central DI or SIADH. Medicare item: 63460.
  • Available
    Echocardiogram
    Assess for heart failure if volume overload suspected. Ejection fraction and diastolic dysfunction evaluation. Medicare item: 55113.

Specialised Testing

💡
Note: Advanced testing typically requires endocrinology consultation and may not be available in all centres.
  • Specialist
    Water Deprivation Test
    Rarely required. Used to distinguish central vs nephrogenic diabetes insipidus in polyuric patients. Requires specialist supervision due to risk of severe dehydration.
  • Specialist
    Saline Suppression Test
    Isotonic saline infusion to assess ADH suppression. Limited availability. Used in research settings to confirm SIADH diagnosis.
  • Specialist
    Fractional Excretion of Uric Acid
    FE-urate >12% suggests SIADH. Calculate as: (Urine urate × Serum creatinine)/(Serum urate × Urine creatinine) × 100.

Additional Tests Based on Clinical Suspicion

Clinical Scenario Additional Investigation Medicare Item
Suspected malignancy Tumour markers (PSA, CEA, CA19-9, LDH), PET-CT 66655-66665, 61541
CNS symptoms Lumbar puncture, EEG 11700, 12203
Suspected medications Drug levels (carbamazepine, phenytoin), liver function tests 66719, 66500-66521
Volume depletion Aldosterone, renin activity ratio 66603, 66604
Chronic illness Liver function tests, albumin, inflammatory markers (CRP, ESR) 66500-66521, 65070
⚠️
Critical: In severe hyponatraemia (<125 mmol/L) or symptomatic patients, perform investigations urgently but do not delay treatment. Paired plasma and urine samples must be collected before initiating therapy for accurate diagnostic interpretation.

Laboratory Interpretation Framework

High Urine Osmolality (>300 mOsm/kg)
  • SIADH (inappropriate ADH secretion)
  • Hypovolaemic hyponatraemia
  • Hypervolaemic hyponatraemia (CHF, cirrhosis)
  • Adrenal insufficiency
  • Severe hypothyroidism
Low Urine Osmolality (<100 mOsm/kg)
  • Primary polydipsia
  • Beer potomania
  • Low solute intake
  • Partial central or nephrogenic DI

Acute Management

🚨
Emergency Management: Severe hyponatraemia (Na⁺ <125 mmol/L) with neurological symptoms requires immediate treatment to prevent cerebral oedema, seizures, and death. Treatment must be individualised based on chronicity, volume status, and severity of symptoms.

Initial Assessment & Stabilisation

1
ABCs & Neurological Assessment
Secure airway if altered conscious state. Assess for seizures, confusion, coma. Consider intubation if GCS <8.
2
Volume Status Assessment
Clinical examination for hypovolaemia, euvolaemia, or hypervolaemia to guide therapy selection.
3
Rapid Investigations
Serum Na⁺, K⁺, glucose, osmolality, urea, creatinine. Urine osmolality, Na⁺, K⁺ if stable.

Severity-Based Treatment Approach

Severe
Na⁺ <125 mmol/L + Symptoms
Seizures, coma, severe altered mental state
ICU/HDU monitoring required
Moderate
Na⁺ 125-129 mmol/L + Symptoms
Nausea, headache, confusion, lethargy
Ward-based monitoring acceptable
Mild
Na⁺ 130-134 mmol/L
Asymptomatic or minimal symptoms
Outpatient management possible

Emergency Hypertonic Saline Therapy

⚠️
Correction Rate Limits: Maximum 10-12 mmol/L increase in first 24 hours. Risk of osmotic demyelination syndrome if correction >18 mmol/L/24h or >25 mmol/L/48h.
💉
Hypertonic Saline 3%
First-line for severe symptomatic hyponatraemia
Bolus Dose 100-150 mL IV over 20 minutes
Target Rise 4-6 mmol/L acutely
Monitoring Na⁺ q2h initially, then q4-6h
Max Rate 1-2 mmol/L/hour initially
Calculation mL = (target Na⁺ - current Na⁺) × wt(kg) × 0.5 ÷ 513
Route Central line preferred, large-bore peripheral acceptable
PBS Status ✓ PBS General Benefit
Hypertonic Saline Protocol
  • Give 100 mL 3% NaCl over 20 minutes
  • Check Na⁺ after 20 minutes
  • Repeat bolus if still severely symptomatic
  • Maximum 3 boluses in 24 hours
  • Switch to maintenance once stable
Stop Criteria
  • Symptom resolution
  • Na⁺ increase ≥5 mmol/L from baseline
  • Na⁺ >125 mmol/L (if severe symptoms resolved)
  • Total increase approaching 10 mmol/L

Volume Status-Specific Management

Hypovolaemic Hyponatraemia

💧
Normal Saline 0.9%
Volume replacement therapy
Initial Rate 250-500 mL/hour IV
Target Restore intravascular volume
Monitoring CVP, urine output, fluid balance
Duration Until euvolaemic
Caution Monitor for rapid Na⁺ rise
PBS Status ✓ PBS General Benefit

Euvolaemic Hyponatraemia (SIADH)

🚫
Fluid Restriction
First-line for SIADH management
Target 500-1000 mL/day
Duration Until Na⁺ normalises
Monitoring Daily weights, fluid balance
Effectiveness Slow correction over 48-72h
Limitation Ineffective in acute severe cases

Hypervolaemic Hyponatraemia

💊
Frusemide
Lasix® · Loop diuretic
Adult Dose 40-80 mg IV
Route IV/Oral
Frequency Once to twice daily
Target Negative fluid balance
Monitoring Electrolytes, creatinine, fluid balance
Renal Adj. Higher doses if eGFR <30
PBS Status ✓ PBS General Benefit

Adjunctive Therapies

🧂
Oral Sodium Chloride
Slow-Sodium® tablets · Maintenance therapy
Adult Dose 1-2 g (17-34 mmol) TDS
Route Oral
Indication Mild-moderate chronic hyponatraemia
Duration Until Na⁺ stabilises >135 mmol/L
Caution Heart failure, hypertension
PBS Status ✓ PBS General Benefit

Monitoring Protocol

Chronic Management

ℹ️
Chronic Hyponatraemia: Defined as hyponatraemia present for >48 hours or of unknown duration. Requires careful, gradual correction to prevent osmotic demyelination syndrome.

Treatment Goals

  • Increase serum sodium by 4-6 mmol/L in first 24 hours
  • Maximum increase of 8-10 mmol/L per day for chronic hyponatraemia
  • Target serum sodium >125 mmol/L for symptom relief
  • Avoid overcorrection (>12 mmol/L/day) to prevent osmotic demyelination

First-Line Therapy by Aetiology

SIADH (Syndrome of Inappropriate ADH Secretion)

💧
Fluid Restriction
First-line SIADH therapy
Restriction 500-800 mL/day
Duration Until sodium normalises
Monitoring Daily weights, sodium q8-12h initially
Efficacy Effective if urine osmolality >500 mOsm/kg
💊
Tolvaptan
Samsca® • V2 receptor antagonist
Adult Dose 15 mg daily, may increase to 30-60 mg daily
Paediatric Not established
Route Oral
Frequency Once daily in morning
Duration Until sodium stable >130 mmol/L
Renal Adj. No adjustment required
Hepatic Adj. Contraindicated in severe impairment
PBS Status ✗ Not PBS listed

Volume Depletion

💧
Normal Saline
0.9% NaCl • Volume replacement
Adult Dose 1-2 L over 24 hours
Paediatric 20 mL/kg bolus, then maintenance
Route Intravenous
Rate 50-100 mL/hour (adjust to response)
Monitoring Sodium q4-6h, fluid balance
PBS Status ✓ PBS General Benefit

Diuretic-Induced

🚫
Diuretic Cessation
Remove causative agent
Action Discontinue thiazide/thiazide-like diuretics
Alternative ACE inhibitor or ARB if BP control needed
Recovery Time 2-7 days typically
Monitoring Daily sodium, BP monitoring

Second-Line Therapies

🧂
Sodium Chloride Tablets
Slow-Na® • Oral sodium supplementation
Adult Dose 2-4 g sodium daily (35-70 mmol)
Paediatric 1-3 mmol/kg/day sodium
Route Oral
Frequency Divided doses with meals
Duration Until sodium stable
Caution Heart failure, hypertension
PBS Status ✓ PBS General Benefit
💊
Demeclocycline
Tetracycline antibiotic • ADH antagonist
Adult Dose 600-1200 mg daily
Paediatric Contraindicated <8 years
Route Oral
Frequency Twice daily
Duration Several weeks for full effect
Renal Adj. Reduce dose if eGFR <30
Side Effects Nephrotoxicity, photosensitivity
PBS Status ⚠ PBS Restricted
💊
Urea
Osmotic agent • Increases free water excretion
Adult Dose 15-30 g daily
Paediatric 0.25-0.5 g/kg/day
Route Oral (dissolved in water/juice)
Frequency Twice daily with meals
Duration Until sodium normalises
Caution Renal impairment, bitter taste
PBS Status ✓ PBS General Benefit
⚠️
Overcorrection Risk: If sodium increases >8-10 mmol/L in 24 hours, consider desmopressin (DDAVP) 1-2 mcg IV/SC and hypotonic fluids to prevent osmotic demyelination syndrome.

Monitoring Protocol

Hours 0-6

  • Monitoring Parameters

    Acute Treatment Monitoring

    ⚠️
    Critical Monitoring: Overcorrection of sodium (>12 mEq/L in 24 hours) can cause osmotic demyelination syndrome. Monitor sodium levels every 2-4 hours during active correction.
    Baseline
    • Serum sodium, osmolality
    • Urine sodium, osmolality, specific gravity
    • Volume status assessment
    • Neurological examination
    • Vital signs including postural BP
    2-4 hours
    • Serum sodium (mandatory during active correction)
    • Neurological status
    • Fluid balance assessment
    • Adjust treatment based on rate of correction
    6-12 hours
    • Serum sodium, potassium, chloride
    • Urine output monitoring
    • Clinical response evaluation
    • Consider desmopressin if overcorrection risk
    24 hours
    • Complete electrolyte panel
    • Calculate total sodium change
    • Assess for complications
    • Plan ongoing management

    Chronic Management Monitoring

    1
    Initial Stabilisation
    • Serum sodium daily until stable
    • Weight and fluid balance
    • Blood pressure monitoring
    • Symptom assessment
    2
    Weekly Monitoring
    • Serum sodium, potassium
    • Urea, creatinine
    • Osmolality if indicated
    • Treatment adherence review
    3
    Monthly Follow-up
    • Complete metabolic panel
    • Thyroid function if relevant
    • Cortisol if adrenal insufficiency
    • Medication review

    Laboratory Monitoring by Cause

    Underlying Cause Key Monitoring Parameters Frequency Australian Lab Availability
    SIADH Serum sodium, urine osmolality, fluid restriction compliance Weekly initially, then monthly All pathology services
    Heart Failure Sodium, BNP/NT-proBNP, weight, LVEF Weekly, echo 6-monthly BNP specialist labs
    Liver Cirrhosis Sodium, albumin, bilirubin, INR, ascites assessment Fortnightly All pathology services
    Hypothyroidism TSH, free T4, sodium Monthly until stable All pathology services
    Adrenal Insufficiency Cortisol, ACTH, sodium, potassium Fortnightly ACTH requires specialist lab
    Thiazide-induced Sodium, potassium, magnesium, glucose Weekly initially All pathology services

    Treatment-Specific Monitoring

    🧂
    Hypertonic Saline (3%)
    Emergency Correction
    Monitoring Sodium every 2 hours, neurological status
    Target Rate 1-2 mEq/L/hour initially, <12 mEq/L/24 hours
    Stop Criteria Symptom resolution or Na+ >125 mEq/L
    💊
    Tolvaptan
    Samsca® · V2 Antagonist
    Baseline Sodium, LFTs, creatinine
    First 24h Sodium every 6-8 hours
    Ongoing Sodium weekly, LFTs monthly
    Alert Stop if ALT >3× ULN

    Complications Surveillance

    🧠
    Osmotic Demyelination Syndrome: Monitor for confusion, dysarthria, dysphagia, weakness, and movement disorders. MRI changes may lag clinical symptoms by 2-6 days.
    • Monitor
      Neurological Assessment
      Glasgow Coma Scale, focal neurology, seizure activity, every 4-6 hours during correction
    • Consider
      Brain MRI
      If neurological deterioration or overcorrection (>12 mEq/L/24h). Available at major hospitals
    • Specialist
      Endocrinology Consult
      For complex cases, recurrent episodes, or underlying endocrine disorders

    Quality Indicators

    Correction Rate
    ≤12 mEq/L per 24 hours
    Australian safety target
    Monitoring Frequency
    Every 2-4 hours during correction
    NSQHS Standard 1
    Target Range
    130-135 mEq/L initial target
    Avoid overcorrection
    📋
    Documentation: Record sodium levels, correction rates, neurological assessments, and treatment adjustments in accordance with NSQHS Standard 6 (Clinical Handover).

Special Populations

🤰 Pregnancy
Physiological Changes Normal pregnancy: serum sodium decreases by 4-5 mmol/L due to reset osmostat and increased ADH sensitivity. Target sodium 130-135 mmol/L in pregnancy.
SIADH Management Fluid restriction first-line. Demeclocycline contraindicated (teratogenic). Tolvaptan: limited safety data - use only if severe hyponatraemia and benefits outweigh risks.
Hyperemesis Gravidarum Common cause of hyponatraemia. IV normal saline preferred. Avoid hypotonic fluids. Monitor electrolytes closely.
Preeclampsia/Eclampsia Hyponatraemia may indicate severe disease. Magnesium sulfate can worsen hyponatraemia. Careful fluid balance required.
👶 Paediatrics
Age-Related Differences Infants more susceptible to cerebral oedema. Neonates: immature renal concentrating ability increases risk. Normal sodium ranges vary by age.
Fluid Restriction Calculate based on body surface area. Infants: 100-120 mL/kg/day baseline. Children: 1500 mL/m²/day. Restrict to 50-70% of maintenance.
Saline Correction 3% saline: 1-2 mL/kg IV over 10-20 minutes for symptomatic severe hyponatraemia. Maximum increase 10-12 mmol/L in first 24 hours.
Common Causes Gastroenteritis with hypotonic fluid replacement, pneumonia (SIADH), meningitis, bronchiolitis, post-operative SIADH.
Tolvaptan Not recommended <12 years. Limited paediatric data. Use only in specialist centres for refractory SIADH.
👴 Elderly (≥65 years)
Increased Risk Factors Age-related decline in renal concentrating ability, polypharmacy, comorbidities. Higher risk of medication-induced SIADH (SSRIs, diuretics, carbamazepine).
Cognitive Effects Mild hyponatraemia (130-134 mmol/L) may cause confusion, falls risk, attention deficits. Often misattributed to dementia.
Fluid Restriction May be poorly tolerated due to medication requirements, swallowing difficulties. Consider 1000-1200 mL/day initially.
Correction Rate More susceptible to osmotic demyelination. Target correction 6-8 mmol/L in first 24 hours. Monitor neurological status closely.
Tolvaptan Start 15 mg daily. Monitor closely for dehydration, hypotension. Drug interactions common in elderly (CYP3A4 inhibitors).
🫘 Renal Impairment
CKD Considerations Reduced concentrating ability increases hyponatraemia risk. Avoid nephrotoxic agents. Monitor for CKD progression.
Tolvaptan Dosing eGFR >30 mL/min/1.73m²: standard dosing. eGFR 10-30: reduce initial dose to 7.5 mg daily. eGFR <10: avoid use.
Dialysis Patients Hyponatraemia between sessions common. Fluid restriction primary management. Adjust dialysate sodium concentration if needed.
Monitoring Check sodium, creatinine, and eGFR more frequently. Avoid rapid correction which may precipitate acute kidney injury.
Diuretic Adjustment Thiazide/thiazide-like diuretics: discontinue if possible. Loop diuretics: reduce dose or hold temporarily during acute management.
🫀 Hepatic Impairment
Cirrhosis Management Dilutional hyponatraemia common due to sodium retention and water accumulation. Fluid restriction challenging due to ascites management needs.
Tolvaptan Child-Pugh A-B: 15 mg daily, monitor LFTs weekly. Child-Pugh C: contraindicated due to hepatotoxicity risk. Avoid in acute liver disease.
Ascites Treatment Paradoxical approach needed - spironolactone and furosemide for volume overload while managing hyponatraemia. Target sodium >125 mmol/L for transplant eligibility.
Hepatic Encephalopathy Hyponatraemia may precipitate or worsen encephalopathy. Lactulose and rifaximin standard therapy. Avoid rapid sodium correction.
Monitoring Daily weights, strict fluid balance. LFTs before tolvaptan and at 2-4 weeks. Discontinue if ALT/AST >3x ULN or bilirubin elevated.
🛡️ Immunocompromised
Increased Infection Risk Higher risk of CNS infections (meningitis, encephalitis) causing SIADH. Consider broader antimicrobial coverage and earlier imaging.
Malignancy-Related SIAD from ectopic ADH secretion (lung, pancreatic, head/neck cancers). Syndrome of Reset Osmostat in chronic illness. Consider paraneoplastic causes.
Medication Interactions Many immunosuppressants cause hyponatraemia (cyclophosphamide, vincristine). Tolvaptan: check interactions with antifungals, antivirals.
Opportunistic Infections Consider Pneumocystis pneumonia, CMV, cryptococcal meningitis as causes of SIADH. Obtain appropriate cultures and serology.
Treatment Modifications Monitor for secondary infections during treatment. Stress-dose steroids may be needed in adrenal insufficiency. Coordinate with oncology/immunology teams.
⚠️
High-Risk Populations: Elderly patients, those with liver disease, and post-neurosurgical patients are at highest risk of osmotic demyelination syndrome. Consider desmopressin to slow correction if sodium rises too rapidly (>10-12 mmol/L in 24 hours).
Pregnancy Sodium Targets
  • First trimester: 135-145 mmol/L
  • Second/third trimester: 130-140 mmol/L
  • Postpartum: return to 135-145 mmol/L
Paediatric Sodium Ranges
  • Neonates (0-28 days): 133-146 mmol/L
  • Infants (1-12 months): 134-144 mmol/L
  • Children (>1 year): 135-145 mmol/L

Complications

🚨
Critical Complications: Cerebral oedema, seizures, coma, osmotic demyelination syndrome (ODS), and respiratory arrest can occur with severe hyponatraemia or rapid correction.

Acute Neurological Complications

Severe
Cerebral Oedema

Mechanism: Rapid or severe hyponatraemia (Na+ <120 mmol/L) causes osmotic water shift into brain cells, leading to increased intracranial pressure.

Clinical features: Headache, nausea, vomiting, altered consciousness, seizures, focal neurological deficits, papilloedema.

Risk factors: Acute onset (<48 hours), elderly patients, premenopausal women, psychiatric patients on psychotropic medications.

ICU monitoring required
Severe
Seizures & Coma

Incidence: Occurs in 10-15% of patients with Na+ <115 mmol/L.

Types: Generalised tonic-clonic seizures, status epilepticus, non-convulsive seizures.

Prognosis: High mortality (>50%) if untreated; permanent neurological sequelae in 15-20% of survivors.

Emergency management

Osmotic Demyelination Syndrome (ODS)

⚠️
Iatrogenic Complication: ODS occurs from overly rapid sodium correction (>10-12 mmol/L in 24 hours or >18 mmol/L in 48 hours).

Central Pontine Myelinolysis

  • Most common form of ODS
  • Affects central pons predominantly
  • Quadriparesis, pseudobulbar palsy
  • "Locked-in" syndrome in severe cases
  • Dysarthria, dysphagia, diplopia

Extrapontine Myelinolysis

  • Affects basal ganglia, thalamus, cerebellum
  • Movement disorders, ataxia
  • Behavioural changes, mutism
  • Parkinsonism, dystonia
  • Can occur alone or with CPM

ODS Risk Factors

High Risk
Patient Factors
Alcoholism, malnutrition, liver disease, elderly, chronic severe hyponatraemia, concurrent hypokalaemia or hypomagnesaemia
Correction
Rate Factors
Correction >10-12 mmol/L/24h, initial serum sodium <120 mmol/L, overcorrection with hypertonic saline

Cardiovascular Complications

  • Monitor
    Cardiac Arrhythmias
    Prolonged QT interval, torsades de pointes, especially with rapid correction or concurrent electrolyte disturbances.
  • Risk
    Hypotension
    Volume depletion in hypovolaemic hyponatraemia; cerebral salt wasting syndrome.
  • Monitor
    Pulmonary Oedema
    Risk with aggressive saline administration in SIADH patients or those with heart failure.

Renal Complications

Complication Mechanism Clinical Impact Management
Acute Kidney Injury Volume depletion, rhabdomyolysis from seizures Reduced GFR, oliguria Volume resuscitation, nephrology consult
Chronic Kidney Disease Recurrent volume depletion, medication nephrotoxicity Progressive GFR decline Regular monitoring, avoid nephrotoxins
Electrolyte Imbalances Concurrent losses, overcorrection Hypokalaemia, hypomagnesaemia Monitor and replace concurrently

Gastrointestinal Complications

🤢
Nausea & Vomiting
Worsening cycle • Fluid loss • Electrolyte depletion
Mechanism Direct CNS effect + increased ICP
Consequence Further sodium and volume losses
Management Ondansetron 4-8 mg IV/PO TDS
Monitoring Fluid balance, daily weights

Long-term Complications

Immediate
(0-72 hours)

Acute cerebral oedema, seizures, coma

Risk of respiratory arrest, aspiration pneumonia

Early
(3-10 days)

Osmotic demyelination syndrome onset

Progressive neurological deterioration, movement disorders

Chronic
(>1 month)

Persistent cognitive impairment

Falls risk, osteoporosis, recurrent hyponatraemia

Long-term
(>6 months)

Quality of life impacts

Increased mortality, healthcare utilisation, disability

Prevention Strategies

✅
Prevention Focus: Most complications are preventable through appropriate recognition, careful correction rates, and monitoring protocols.
1
Early Recognition
Regular electrolyte monitoring in high-risk patients, awareness of medication-induced hyponatraemia
2
Controlled Correction
Limit sodium rise to 6-8 mmol/L in first 24 hours, 12-14 mmol/L in high-risk patients
3
Monitoring Protocol
4-6 hourly sodium levels during active treatment, neurological observations, fluid balance
4
Concurrent Management
Replace potassium and magnesium, manage underlying conditions, avoid precipitating factors
💡
Australian Context: In remote and rural areas, early recognition and appropriate initial management before transfer to tertiary centres is crucial for preventing severe complications.

Follow-Up & Prevention

ℹ️
Key Principle: Follow-up frequency depends on severity, underlying cause, and treatment response. Prevention focuses on addressing modifiable risk factors and patient education.

Follow-Up Schedule

Severe Hyponatraemia
<125 mmol/L or Symptomatic
Hourly electrolytes during active correction, then 4-6 hourly until stable
Inpatient monitoring required
Moderate Hyponatraemia
125-129 mmol/L
Daily electrolytes until stable, then weekly for 2-4 weeks
Outpatient possible if asymptomatic
Mild Hyponatraemia
130-134 mmol/L
Weekly monitoring until stable, then monthly
Outpatient management appropriate

Long-term Monitoring Parameters

  • Essential
    Serum Electrolytes
    Sodium, potassium, chloride, bicarbonate. Frequency based on stability and underlying cause.
  • Essential
    Renal Function
    Creatinine, eGFR to monitor for CKD progression or AKI.
  • Available
    Serum Osmolality
    If SIADH suspected or during treatment monitoring.
  • Available
    Urine Osmolality/Sodium
    For ongoing assessment of underlying cause, particularly in SIADH.
  • Specialist
    Thyroid Function
    TSH, T4 if hypothyroidism contributing factor.
  • Specialist
    Cortisol Assessment
    If adrenal insufficiency suspected or confirmed.

Follow-Up Timeline

24-48 hours
Early follow-up: Electrolyte recheck, symptom assessment, medication review. Ensure correction rate appropriate (<10-12 mmol/L in 24h).
1 week
Short-term: Assess treatment response, medication tolerance, underlying cause management. Adjust therapy as needed.
2-4 weeks
Stabilisation: Confirm sodium normalisation, review ongoing treatment needs, assess for complications.
3 months
Medium-term: Comprehensive review of underlying conditions, medication optimisation, prevention strategies.
6-12 months
Long-term: Ongoing monitoring based on underlying cause. Annual review if chronic condition requiring long-term management.

Prevention Strategies

Primary Prevention
  • Medication review and counselling on drugs causing hyponatraemia
  • Patient education on appropriate fluid intake
  • Management of underlying medical conditions (heart failure, liver disease, hypothyroidism)
  • Regular monitoring in high-risk patients (elderly, multiple medications)
  • Thiazide diuretic monitoring protocols
Secondary Prevention
  • Identify and address precipitating factors
  • Optimise treatment of underlying conditions
  • Regular electrolyte monitoring protocols
  • Patient self-monitoring education where appropriate
  • Medication adherence support

Patient Education Priorities

1
Fluid Management
Educate on appropriate fluid intake based on individual needs. Avoid excessive water consumption, especially during exercise or illness.
2
Medication Awareness
Understanding of medications that can cause hyponatraemia. Importance of not stopping prescribed medications without medical consultation.
3
Symptom Recognition
Early recognition of hyponatraemia symptoms (headache, nausea, confusion, weakness) and when to seek medical attention.
4
Follow-up Compliance
Importance of regular monitoring and blood tests. Understanding why frequent monitoring is necessary initially.
⚠️
Red Flag Symptoms for Urgent Review: Severe headache, vomiting, altered consciousness, seizures, falls, or rapid symptom deterioration require immediate medical assessment.

Discharge Planning Considerations

  • Medication reconciliation: Review all medications for those contributing to hyponatraemia
  • GP communication: Clear discharge summary including cause, treatment, and monitoring requirements
  • Follow-up arrangements: Scheduled appointments with appropriate frequency
  • Laboratory arrangements: Pre-arranged blood tests with results pathway
  • Emergency contacts: Clear instructions on when and how to seek urgent care
  • Specialist referral: If underlying endocrine or complex medical conditions require ongoing management

Quality Improvement Measures

Hospital-acquired hyponatraemia
Monitor and audit rates
Monthly review
Focus on preventable causes
Medication-induced cases
Prescribing protocols
Ongoing
Thiazide monitoring guidelines
Overcorrection events
Treatment protocols
Case review
Prevent osmotic demyelination
✅
Successful Long-term Management: Maintains sodium 135-145 mmol/L, prevents recurrence, manages underlying conditions effectively, and ensures patient understanding of condition and treatment.

References

  • 01
    Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1-47. doi:10.1530/EJE-13-1020
  • 02
    Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-42. doi:10.1016/j.amjmed.2013.07.006
  • 03
    Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-1589. doi:10.1056/NEJM200005253422107
  • 04
    Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28(5):1340-1349. doi:10.1681/ASN.2016101139
  • 05
    Australian Institute of Health and Welfare. Chronic kidney disease compendium. Canberra: AIHW; 2023. Available from: https://www.aihw.gov.au/reports/chronic-kidney-disease
  • 06
    Pharmaceutical Benefits Scheme. Tolvaptan - PBS listing and restrictions. Canberra: Australian Government Department of Health; 2023. Available from: https://www.pbs.gov.au
  • 07
    Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med. 1986;314(24):1535-1542. doi:10.1056/NEJM198606123142402
  • 08
    Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One. 2013;8(12):e80451. doi:10.1371/journal.pone.0080451
  • 09
    Ball SG, Iqbal Z. Diagnosis and treatment of hyponatraemia. Best Pract Res Clin Endocrinol Metab. 2016;30(2):161-173. doi:10.1016/j.beem.2016.02.014
  • 10
    Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards User Guide for Medication Safety. Sydney: ACSQHC; 2019.
  • 11
    Miller M, Hecker MS, Friedlander DA, Carter MJ. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc. 1996;44(4):404-408. doi:10.1111/j.1532-5415.1996.tb06407.x
  • 12
    Tzoulis P, Bagkeris E, Bouloux PM. A case-control study of hyponatraemia as an independent risk factor for inpatient mortality. Clin Endocrinol (Oxf). 2014;81(3):401-407. doi:10.1111/cen.12429
  • 13
    Sahay M, Sahay R. Hyponatremia: A practical approach. Indian J Endocrinol Metab. 2014;18(6):760-771. doi:10.4103/2230-8210.141320
  • 14
    National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Melbourne: NHMRC; 2013.
  • 15
    Rosner MH, Kirven J. Exercise-associated hyponatremia. Clin J Am Soc Nephrol. 2007;2(1):151-161. doi:10.2215/CJN.02730806